AAAdeyinka Charles Adejumo

Adeyinka Charles Adejumo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Adeyinka Charles Adejumo has a total of 75 co-authors. Here are the top co-authors by number of shared publications:

  • Kelechi Lauretta Adejumo

    School of Public Health, University of Massachusetts Lowell, Lowell, MA, United States

    4 shared publications
  • Oluwole Adegbala

    Department of Internal Medicine, Englewood Hospital and Medical Center, Seton Hall University-Hackensack Meridian School of Medicine, Englewood, New Jersey

    4 shared publications
  • Adedayo Adeboye

    WJB Dorn VAMC Heart and Vascular Institute/USC School of Medicine, Columbia, SC, United States

    3 shared publications
  • Donghee Kim

    Division of Gastroenterology and Hepatology Stanford University School of Medicine Stanford California USA

    3 shared publications
  • Emmanuel Akintoye

    Department of Medicine, Division of Cardiovascular Medicine, University of Iowa, Hospitals and Clinics, Iowa, Iowa

    3 shared publications
  • Karlene Williams

    Department of Internal Medicine, Englewood Hospital and Medical Center, Seton Hall University-Hackensack Meridian School of Medicine, Englewood, New Jersey

    3 shared publications

Latest Publications

  • The road to pandemic recovery: Tracking COVID-19’s impact on cirrhosis care and outcomes among 111,558 Veterans

    by Adeyinka C. Adejumo, Vera Yakovchenko, Timothy R. Morgan, Patrick Spoutz, Linda Chia, Jasmohan S. Bajaj, Michael F. Chang, Jason A. Dominitz, Shari S. Rogal

    Background & Aims: This study aimed to evaluate quarterly trends in process and health outcomes among Veterans with cirrhosis and assess the factors associated with cirrhosis outcomes before and during the COVID-19 pandemic. Approach & Results: US Veterans with cirrhosis were identified using the Veterans Health Administration Corporate Data Warehouse. Quarterly measures were evaluated from September 30, 2018, through March 31, 2022, including twice yearly screening for hepatocellular carcinoma (HCC-6), new HCC, surveillance for or treatment of esophageal varices, variceal bleeding, all-cause hospitalization, and mortality. Joinpoint analyses were used to assess the changes in trends over time. Logistic regression models were used to identify the demographic and medical factors associated with each outcome over time. Among 111,558 Veterans with cirrhosis with a mean Model for End-stage Liver Disease-Sodium of 11±5, rates of HCC-6 sharply declined from a prepandemic peak of 41%, to a nadir of 28%, and rebounded to 36% by March 2022. All-cause mortality did not significantly change over the pandemic, but new HCC diagnosis, EVST, variceal bleeding, and all-cause hospitalization significantly declined over follow-up. Quarterly HCC diagnosis declined from 0.49% to 0.38%, EVST from 50% to 41%, variceal bleeding from 0.15% to 0.11%, and hospitalization from 9% to 5%. Rurality became newly, significantly associated with nonscreening over the pandemic (aOR for HCC−6=0.80, 95% CI 0.74 to 0.86; aOR for EVST=0.95, 95% CI 0.90 to 0.997). Conclusions: The pandemic continues to impact cirrhosis care. Identifying populations at the highest risk of care disruptions may help to address ongoing areas of need.


  • Gender and Racial Differences in Hospitalizations for Primary Biliary Cholangitis in the USA

    by Adeyinka Charles Adejumo, Daud H. Akhtar, Brittany B. Dennis, George Cholankeril, Quazim Alayo, Olumuyiwa A. Ogundipe, Donghee Kim, Aijaz Ahmed

    Background/Aim The prevalence, characteristics, burden and trends of primary biliary cholangitis (PBC) hospitalizations in the USA remain unclear. Method We identified primary PBC hospitalizations from the National Inpatient Sample (NIS) 2007 through 2014 using ICD-9-CM codes. We calculated the rates and trends of hospitalization for PBC per 100,000 US population among each gender (males and females) and racial categories (Whites, Blacks, Hispanics and other racial minorities), and measured the predictors of hospitalization, and of mortality, charges and length of stay (LOS) among PBC hospitalizations. Result There were 8460 (weighted: 41,191) PBC hospitalizations between 2007 and 2014. The mean national PBC hospitalization rate was 2.2 cases per 100,000 population (2.2/100,000), increasing from 1.7/100,000 (2007) to 2.5/100,000 (2014). From 2007 to 2014, the in-hospital mortality and LOS were unchanged while the charges increased from $65,993 to $73,093 ($225 million to $447 million overall expenses). Compared to Whites, the PBC hospitalization rate was 12% higher among Hispanics (RR: 1.12 [1.09–1.16]), 53% lower in Blacks (RR: 0.47 [0.45–0.49]) and 5% lower among other racial minorities (0.95 [0.91–0.99]). The rate was higher among females (RR:4.02 [3.93–4.12]) compared to males. On multivariate analysis, Blacks and other racial minorities, respectively, had higher odds of mortality (AOR: 1.47 [1.03–2.10] and 1.33 [0.96–1.84]), while other racial minorities had longer LOS (7.0 vs. 5.6 days) and higher hospital charges ($48,984 vs. $41,495) when compared to Whites. Conclusion The hospitalization rate and burden of PBC in the USA have increased disproportionately among females and Hispanics with higher mortality in Blacks.


  • Predictors, burden and impact of cardiac arrhythmias among patients hospitalized with end-stage liver disease

    by Adeyinka Charles Adejumo, Kelechi Lauretta Adejumo, Olalekan Akanbi, Oluwole Muyiwa Adegbala, Quazim Adegbola Alayo, Daniel Obadare Fijabi, Olumuyiwa Akinbolaji Ogundipe, Nureddin Almaddah, Lydie Pani, Adedayo Adeboye


  • Suboptimal Use of Inpatient Palliative Care Consultation May Lead to Higher Readmissions and Costs in End-Stage Liver Disease

    by Adeyinka Charles Adejumo, Donghee Kim, Umair Iqbal, Eric R. Yoo, Brian C. Boursiquot, George Cholankeril, Robert J. Wong, Paul Y. Kwo, Aijaz Ahmed

    Background/Aims: Patients with end-stage liver disease (ESLD) have a high risk for readmission. We studied the role of palliative care consultation (PCC) in ESLD-related readmissions with a focus on health care resource utilization in the United States. Methods: We performed a retrospective longitudinal analysis on patients surviving hospitalizations with ESLD from January 2010 to September 2014 utilizing the Nationwide Readmissions Database with a 90-day follow-up after discharge. We analyzed annual trends in PCC among patients with ESLD. We matched PCC to no-PCC (1:1) using propensity scores to create a pseudorandomized clinical study. We estimated the impact of PCC on readmission rates (30- and 90-day), and length of stay (LOS) and cost during subsequent readmissions. Results: Of the 67,480 hospitalizations with ESLD, 3485 (5.3%) received PCC, with an annual increase from 3.6% to 6.7% ( p for trend p < 0.01) and cost (US $48,752 vs. US $75,810 and US $48,582 vs. US $69,035, p < 0.01). Conclusion: Inpatient utilization of PCC for ESLD is increasing annually, yet still remains low in the United States. More importantly, PCC was associated with a decline in readmission rates resulting in a lower burden on health care resource utilization and improvement in cost savings during subsequent readmissions.


  • Readmission Rates and Associated Outcomes for Alcoholic Hepatitis: A Nationwide Cohort Study

    by Adeyinka C. Adejumo, George Cholankeril, Umair Iqbal, Eric R. Yoo, Brian C. Boursiquot, Waldo C. Concepcion, Donghee Kim, Aijaz Ahmed

    Background/Aims Alcoholic hepatitis (AH) can lead to sudden and severe hepatic decompensation necessitating recurrent hospitalizations. We evaluated the trends, predictors, and healthcare cost burden of AH-related readmissions in the USA. Methods Utilizing the National Readmissions Database 2010–2014, we performed a retrospective longitudinal analysis to identify the index readmission with AH for up to 90 days after discharge. Annual trends of 30- and 90-day AH-related readmissions were calculated. Predictors of 30- and 90-day readmission were determined by multivariate logistic regression. Annual healthcare cost burden associated with AH-linked readmissions was estimated. Results Of the 21,572 (unweighted: 50,769) AH-related hospitalizations, 4917 (22.8%) and 7890 (36.6%) were readmitted in 30 and 90 day, respectively, with rates that were statistically unchanged from 2010 to 2014. Predictors of 30-day readmissions included female gender, hepatitis C virus infection, cirrhosis, ascites, acute kidney injury, urinary tract infection, history of bariatric surgery, chronic pancreatitis, and high medical comorbidity index. Acute pancreatitis and palliative care consultation were associated with a lower risk of 30-day readmission. Predictors of 90-day readmission were similar to risk factors for 30-day readmission. From 2010 to 2014, the annual cost (and total hospitalization days) burden increased in 2014 to $164 million (22,244 days) and $321 million (42,772 days) for 30- and 90-day AH-related readmissions, respectively. Conclusion Despite relatively stable trends in AH-related readmission, the total LOS and cost has been rising. A target-directed approach with a focus on high-risk subpopulations may help understand the unique challenges associated with the rising cost of AH-related readmissions.


  • Inferior Outcomes of Patients With Acute Myocardial Infarction and Comorbid Protein‐Energy Malnutrition

    by Adeyinka Charles Adejumo, Kelechi Lauretta Adejumo, Oluwole Muyiwa Adegbala, Ngozi Enwerem, Andrew Ofosu, Olalekan Akanbi, Daniel Obadare Fijabi, Olumuyiwa Akinbolaji Ogundipe, Lydie Pani, Adedayo Adeboye

    Background: Protein‐energy malnutrition (PEM) diminishes amino acid and energy availability, impairing the body's healing capability after injury, such as in myocardial damage following acute myocardial infarction (AMI).Aims: We sought to investigate the influence of PEM on clinical outcomes of AMI.Methods: We identified records with a primary discharge diagnosis of AMI from the Nationwide Inpatient Sample (2012–2014), stratified by concomitant PEM. We matched PEM to no‐PEM (1:1) using a greedy algorithm–based propensity methodology and estimated the impact of PEM on health outcomes (SAS 9.4).Results: Of the 332,644 hospitalizations for AMI, 11,675 had concomitant PEM accounting for roughly $US 1.5 billion and over 119,792 hospital days. PEM was associated with older age (74.43‐ vs. 66.90‐years; P < 0.0001), female sex (49.19% vs. 38.44%; P < 0.0001), black race (12.78% vs. 10.46%; P < 0.0001), and higher comorbidity burden (Deyo > 3: 32.77% vs. 16.69%; P < 0.0001). After propensity matching, PEM was associated with higher mortality (Adjusted odds ratio [AOR]: 1.59 [1.46–1.73]), cardiogenic shock (AOR: 2.26 [2.08–2.44]), discharge to secondary facilities (AOR: 2.21 [2.10–2.33]), charges ($135,500 [$131,956–139,139] vs. $81,084 [$79,241–82,970]), cardiac artery bypass surgery (AOR:1.81 [1.66–1.97]), intra‐aortic balloon pump placement (AOR: 1.83 [1.65–2.04]) and longer length of stay (10.15‐ vs. 5.52‐days).Conclusions: PEM is a predisposing factor for devastating clinical outcomes among AMI hospitalizations. Higher prevention, identification and management of PEM among high‐risk individuals (older age, female sex, and black race) residing in the community are needed.


  • Characteristics and Outcomes of Patients With Cardiogenic Shock Utilizing Hemodialysis for Acute Kidney Injury

    by Oluwole Adegbala, Chakradhari Inampudi, Adeyinka Adejumo, Gene Otuonye, Emmanuel Akintoye, Razan Elsayed, Karlene Williams, Paulino Alvarez, Luis Afonso, Alexandros Briasoulis


  • Biomarkers of Macrophage Activation and Immune Danger Signals Predict Clinical Outcomes in Alcoholic Hepatitis

    by Banishree Saha, David Tornai, Karen Kodys, Adeyinka Adejumo, Patrick Lowe, Craig McClain, Mack Mitchell, Arthur McCullough, Srinivasan Dasarathy, Aimee Kroll‐Desrosiers, et al.

    Although mortality due to acute alcoholic hepatitis (AH) correlates with Model for End‐Stage Liver Disease (MELD) scores, biomarkers are critically needed to manage this disease. Increases in inflammatory markers and macrophage activation are associated with acute AH and could be potential biomarkers of clinical events and/or mortality. We enrolled 89 clinically diagnosed AH patients in four US academic medical centers. Plasma from AH patients had a significant increase in gut microbial translocation indicators (endotoxin, bacterial 16S ribosomal DNA) and host response indicators (soluble cluster of differentiation 14 [sCD14] and lipopolysaccharide binding protein [LBP]) compared to controls. Patient MELD score and Glasgow Alcoholic Hepatitis score (GAHS) correlated with endotoxin levels. AH patients also had a significant increase in high mobility group protein 1 (HMGB1), a sterile danger signal molecule, and osteopontin (OPN), a multifunctional phosphoprotein involved in neutrophil activation, compared to controls. Increased levels of OPN positively correlated with increasing MELD score, GAHS, and LBP levels. Consistent with these results, AH patients had significantly increased circulating levels of macrophage activation (sCD163 and sCD206) markers compared to healthy controls, and sCD163 and sCD206 significantly and positively correlated with OPN, HMGB1, and LBP levels as well as with MELD score and GAHS. These findings indicate a connection between microbial translocation, immune cell activation, and AH severity. Plasma sCD14, OPN, sCD163, and sCD206 levels were significantly higher in nonsurvivors than survivors. In multivariate regression models, we identified sCD14, sCD163, and OPN as independent predictors of 90‐day mortality, infection, and organ failure development, respectively. Conclusion: Our study suggests that sCD14, LBP, OPN, sCD163, and sCD206 are biomarkers to indicate severity and predict clinical outcomes in AH.


  • Protein-Energy Malnutrition and Outcomes of Hospitalizations for Heart Failure in the USA

    by Adeyinka Charles Adejumo, Kelechi Lauretta Adejumo, Oluwole Muyiwa Adegbala, Ifeanyichukwu Chinedozi, Jordan Ndansi, Olalekan Akanbi, Nnaemeka Egbuna Onyeakusi, Olumuyiwa Akinbolaji Ogundipe, Tamunoinemi Bob-Manuel, Adedayo Adeboye